Stage III Melanoma


Yervoy® Improves Overall Survival in Fully Resected Stage III Melanoma Patients (October 24, 2016)

Results were presented during the 2016 European Society for Medical Oncology Congress demonstrating that Yervoy® (ipilimumab) compared to placebo improves survival in stage III melanoma patients who are... Continue Reading

Epacadostat Plus Keytruda® Appears Effective in Melanoma (October 11, 2016)

The treatment combination consisting of epacadostat plus Keytruda® (pembrolizumab) appears effective in the treatment of advanced melanoma. Melanoma is a type of skin cancer that often starts in the form... Continue Reading

Cotellic®/Zelboraf® Combo: New Standard of Care for Melanoma (September 20, 2016)

The treatment combination consisting of Cotellic® (cobimetinib) plus Zelboraf® (vemurafenib) improves overall survival for patients with advanced, BRAF (V600) mutation-positive melanoma. These confirmatory... Continue Reading

Check It Out: May is Skin Cancer Awareness Month (May 3, 2016)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around... Continue Reading

Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma (December 2, 2015)

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which... Continue Reading

Yervoy Gets Expanded Approval for Earlier-Stage Melanoma (November 9, 2015)

The United States Food and Drug Administration (FDA) has expanded the approval indication for Yervoy (ipilimumab) to include treatment of stage III melanoma. Melanoma is the most deadly form of skin cancer,... Continue Reading

MRA Hails FDA Approval of First Combination Immunotherapy for Melanoma (October 1, 2015)

The Melanoma Research Alliance (MRA) welcomes the U.S. Food and Drug Administration (FDA) decision to approve the use of Bristol-Myers Squibb’s (BMS) nivolumab (Opdivo®) and ipilimumab (Yervoy®) in... Continue Reading

Melanoma Support Community: Information, Support, Hope (September 30, 2015)

  Post questions, comment on discussions and find support about living with melanoma by signing up for CancerConnect’s Melanoma Community. Registering with CancerConnect is fast, free and confidential.... Continue Reading

New Combination Treatment Effective Against Melanoma Skin Metastases (August 18, 2015)

In findings never before seen in melanoma, a novel combination therapy was found to be highly effective at treating patients with skin metastases, new research from UC Davis has shown. Led by Emanual Maverakis... Continue Reading

Opdivo® Alone or Combined with Yervoy® Effective in Advanced Melanoma (June 29, 2015)

Opdivo® (nivolumab) used alone or in combination with Yervoy® (ipilimumab) appears to extend progression-free survival in patients with advanced melanoma. These findings were presented at 2015 Annual... Continue Reading

Melanoma Drug T-VEC Receives Recommendation for FDA Approval (May 1, 2015)

An advisory panel to the U.S. Food and Drug Administration (FDA) has recommended approval of the investigational drug T-VEC (talimogene laherparepvec) for the treatment of metastatic melanoma. Biopharmaceutical... Continue Reading

National Melanoma Awareness Month on CancerConnect (May 1, 2015)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of melanoma educational programs for national melanoma awareness month. As the month of May brings melanoma into... Continue Reading

Keytruda® May Be More Effective than Yervoy® in Advanced Melanoma (April 20, 2015)

Keytruda® (pembrolizumab) appears to outperform Yervoy® (ipilimumab) at initial treatment of patients with advanced melanoma. Pharmaceutical company Merck announced these Phase III clinical trial findings... Continue Reading

References for Melanoma (February 12, 2015)

1 Wagner JD, Gordon MS, Chuang TY, et al.: Current therapy of cutaneous melanoma. Plast Reconstr Surg 105 (5): 1774-99; quiz 1800-1, 2000. 2 Cohn-Cedermark G, Rutqvist LE, Andersson R, et al.: Long term... Continue Reading

Yervoy® Improves Treatment of Stage III Melanoma (February 6, 2015)

CancerConnect News: The first trial of the immunomodulator Yervoy® (ipilimumab) conducted in patients with stage III melanoma appears promising, demonstrating an improvement by delaying cancer recurrence... Continue Reading

Melanoma Research News: Year in Review (January 7, 2015)

After several years of exciting developments in melanoma therapy, progress continued throughout 2014. Doctors specializing in the treatment of melanoma reported continued progress about optimizing the... Continue Reading

Yervoy® May be Beneficial in Uveal Melanoma (December 8, 2014)

CancerConnect News:The first trial of the immunomodulator Yervoy® (ipilimumab) conducted in patients with uveal melanoma appears promising in according to the results of a small clinical trial presented... Continue Reading

Adjuvant Treatment of Stage III Disease (December 1, 2014)

It is important to understand that many patients with stage III melanoma are at high risk for disease recurrence because undetectable cancer cells referred to as micrometastases may have already broken... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS